title: Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.
abstract: After nearly three decades with little change in the treatment for B-cell non-Hodgkin's lymphoma, the addition of immunotherapy has had a profound effect on the treatment of this group of diseases. A more subtle addition to the armentarium has been the radiolabeled monoclonal antibodies, (90)yttrium ibritumomab tiuxetan and (131)iodine tositumomab. Unfortunately these drugs have been underutilized. This is, in part, because of the need for coordination between specialties, concern about long-term effects, possible limitations on the tolerance of subsequent therapies and, in part, because of reimbursement factors. In this review, the studies in relapsed and refractory disease are discussed and the very promising results reported from phase II studies using radioimmunotherapy as first-line. Potential mechanisms of resistance to monoclonal antibodies are postulated based on alterations in cell signaling pathways that have been observed in lymphoma cell lines resistant to rituximab. It is anticipated that as mechanisms of resistance are better understood for both unlabeled and labeled monoclonal antibodies, biomarkers will not only predict their efficacy but also lead to the development of therapies to overcome resistance.
authors.affiliation: University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA, USA.
authors.forename: Samuel A
authors.initials: SA
authors.lastname: Jacobs
references.citation: Cancer Immunol Immunother. 2006 Dec;55(12):1451-8
references.pmid: 16496145
references.citation: Nature. 2000 Feb 3;403(6769):503-11
references.pmid: 10676951
references.citation: Clin Nucl Med. 2000 Nov;25(11):866-9
references.pmid: 11079581
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4418-25
references.pmid: 16940276
references.citation: J Clin Oncol. 2007 Feb 10;25(5):579-86
references.pmid: 17242396
references.citation: J Biol Chem. 2005 Sep 2;280(35):31182-9
references.pmid: 16000298
references.citation: J Clin Oncol. 1998 Aug;16(8):2825-33
references.pmid: 9704735
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1263-70
references.pmid: 12663713
references.citation: CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27
references.pmid: 8548526
references.citation: Blood. 2002 Jun 15;99(12):4336-42
references.pmid: 12036859
references.citation: Blood. 2000 Jun 15;95(12):3900-8
references.pmid: 10845926
references.citation: J Clin Oncol. 1999 Dec;17(12):3793-803
references.pmid: 10577851
references.citation: Ann Rheum Dis. 2007 Mar;66(3):351-7
references.pmid: 16950808
references.citation: J Clin Oncol. 2002 Aug 15;20(16):3545-57
references.pmid: 12177115
references.citation: Cancer Res. 2007 Feb 1;67(3):1335-43
references.pmid: 17283171
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3918-28
references.pmid: 11579112
references.citation: Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9
references.pmid: 16761929
references.citation: Cancer Res. 2004 Oct 1;64(19):7117-26
references.pmid: 15466208
references.citation: Mod Pathol. 2000 Feb;13(2):193-207
references.pmid: 10697278
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3940-7
references.pmid: 12975461
references.citation: J Clin Invest. 2002 Jul;110(1):71-9
references.pmid: 12093890
references.citation: Clin Cancer Res. 2000 Feb;6(2):701-8
references.pmid: 10690556
references.citation: Science. 1993 Oct 29;262(5134):747-50
references.pmid: 8235596
references.citation: Cancer Immunol Immunother. 2003 May;52(5):309-16
references.pmid: 12700946
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5696-704
references.pmid: 16110029
references.citation: N Engl J Med. 2005 Feb 3;352(5):441-9
references.pmid: 15689582
references.citation: Blood. 2002 Feb 1;99(3):754-8
references.pmid: 11806974
references.citation: Blood. 2004 Sep 1;104(5):1258-65
references.pmid: 15126323
references.citation: Blood. 2005 Oct 15;106(8):2896-902
references.pmid: 16002426
references.citation: Blood. 2004 Nov 1;104(9):2635-42
references.pmid: 15226177
references.citation: Ann Oncol. 1999 Jun;10(6):655-61
references.pmid: 10442187
references.citation: Blood. 2003 Oct 1;102(7):2351-7
references.pmid: 12750161
references.citation: Ann Oncol. 2001 Jan;12(1):109-14
references.pmid: 11249036
references.citation: Blood. 1994 Jan 15;83(2):435-45
references.pmid: 7506951
references.citation: Blood. 2000 Nov 1;96(9):2934-42
references.pmid: 11049969
references.citation: Blood. 2005 Jun 15;105(12):4576-82
references.pmid: 15731177
references.citation: Cancer. 2002 Feb 15;94(4 Suppl):1363-72
references.pmid: 11877767
references.citation: Clin Cancer Res. 2004 Dec 1;10(23):7792-8
references.pmid: 15585610
references.citation: Semin Nucl Med. 2002 Oct;32(4):293-321
references.pmid: 12524653
references.citation: Ann Hematol. 2005 Jan;84(1):1-12
references.pmid: 15480663
references.citation: J Clin Immunol. 2002 May;22(3):124-30
references.pmid: 12078853
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7146s-7150s
references.pmid: 16203814
references.citation: Blood. 1999 Oct 1;94(7):2217-24
references.pmid: 10498591
references.citation: J Clin Oncol. 2002 May 15;20(10):2453-63
references.pmid: 12011122
references.citation: Blood. 2007 Jul 1;110(1):54-8
references.pmid: 17387223
references.citation: Blood. 1997 Jul 1;90(1):244-51
references.pmid: 9207459
references.citation: Int J Oncol. 1999 Nov;15(5):1017-25
references.pmid: 10536187
references.citation: Clin Chest Med. 1990 Mar;11(1):65-71
references.pmid: 2182279
references.citation: Cancer Res. 2005 Jan 1;65(1):264-76
references.pmid: 15665303
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3262-9
references.pmid: 12149300
references.citation: J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27
references.pmid: 16204691
references.citation: J Clin Oncol. 1995 Oct;13(10):2656-75
references.pmid: 7595720
references.citation: J Radiat Res. 2005 Jun;46(2):241-8
references.pmid: 15988143
references.citation: J Clin Oncol. 2000 Mar;18(6):1316-23
references.pmid: 10715303
references.citation: Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1187-203
references.pmid: 7713782
references.citation: Cancer. 2006 Jul 15;107(2):433-8
references.pmid: 16770786
references.citation: Blood. 2004 Oct 15;104(8):2269-71
references.pmid: 15166030
references.citation: J Exp Med. 2002 Jun 17;195(12):1653-9
references.pmid: 12070293
references.citation: J Clin Oncol. 1999 Jun;17(6):1851-7
references.pmid: 10561225
references.citation: Blood. 2000 Aug 15;96(4):1259-66
references.pmid: 10942366
references.citation: J Exp Ther Oncol. 2004 Dec;4(4):305-16
references.pmid: 15844660
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4143-9
references.pmid: 16896003
references.citation: J Immunol. 1985 Dec;135(6):3795-801
references.pmid: 2415587
references.citation: J Immunother. 2001 May-Jun;24(3):263-71
references.pmid: 11394505
references.citation: J Clin Oncol. 2007 Feb 10;25(5):571-8
references.pmid: 17242397
references.citation: J Clin Oncol. 2005 Jan 20;23(3):461-7
references.pmid: 15534357
references.citation: Blood. 2006 Sep 15;108(6):1975-8
references.pmid: 16705086
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3885-90
references.pmid: 12228209
references.citation: Blood. 2001 Dec 1;98(12):3383-9
references.pmid: 11719378
references.citation: J Clin Oncol. 1998 Aug;16(8):2780-95
references.pmid: 9704731
references.citation: Cancer Res. 2007 Feb 1;67(3):1270-81
references.pmid: 17283164
references.citation: J Clin Oncol. 2012 Sep 1;30(25):3119-26
references.pmid: 22851557